Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of dose-dense sequential FEC and docetaxel in high-risk operable breast cancer
2005-001876-11Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Jul 2005
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, fluorouracil, epirubicin, cyclophosphamide and pegfilgrastim in breast cancer (2 arms), sponsored by UZ Leuven. Primary endpoint: Completion of intended treatment at adequate relative dose intensity. Started Jul 2005; status: completed.
02
Drugs
docetaxelfluorouracilepirubicincyclophosphamidepegfilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-001876-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001876-11.